Skip to main content
. 2020 Apr 20;64(10):1901135. doi: 10.1002/mnfr.201901135

Table 3.

Post‐treatment differences in urinary excretion of (epi)catechin and HGVL metabolites 28 days after daily ingestion of the high‐ and low‐dose EPC and OPC treatments and placebo

High dose EPC Low dose EPC OPC Placebo
(+) Catechin 0.0 0.0 0.0 0.0
(‒)‐Epicatechin 0.0 0.0 0.0 0.0
(Epi)catechin‐di‐glucuronide 0.0 0.0 0.0 0.0
Methyl (epi)catechin 0.0 0.0 0.0 0.0
Methyl (epi)catechin‐sulfate 0.0 0.0 0.0 0.0
(Epi)catechin‐sulfate 110.5 (44.8–170.8) 53.7 (15.3–95.2) 2.0 (0.8–3.1) 0.3 (0.1–1.0)
(Epi)catechin‐methyl‐sulfate 74.6 (44.9–129.8) 36.9 (24.7–63.0) 1.4 (0.6–2.1) 0.5 (0.1–1.2)
(Epi)catechin glucuronide 45.8 (29.3–77.8) 19.2 (10.2–35.1) 0.1 (0.1–0.4) 0.1 (0.0–0.2)
(Epi)catechin‐sulfate‐glucuronide 13.8 (7.2–23.6) 4.0 (3.0–9.4) 0.1 (0.0–0.2) 0.0 (0.0–0.1)
(Epi)catechin‐di‐sulfate 0.57 (0.2–1.5) 0.7 (0.2–1.5) 0.0 0.0
Median of (epi)catechin metabolites 267.2 (147.8–405.9) 109.3 (61.3–213.3) 3.6 (1.8–5.7) 1.0 (0.3–3.2)
3,4DHVL 3′‐ sulfate 38.4 (20.1–74.8) 25.1 (13.9–62.5) 5.2 (1.7–16.3) 1.3 (0.3–4.4)
3,4DHVL 4′‐glucuronide 16.0. (7.9–32.1) 7.6 (3.1–20.8) 1.2 (0.4–3.6) 0.3 (0.1–1.0)
3,4DHVL 3′‐glucuronide 36.0 (14.9–56.3) 14.4 (6.4–35.1) 2.0 (0.8–3.4) 0.3 (0.1–1.5)
3,4DHVL 0.6 (0.3–1.1) 0.4 (0.2–0.6) 0.1 (0.0–0.2) 0.0 (0.0–0.1)
4H3MVL 0.0 0.0 0.0 0.0
Median of HGVL metabolites 99.9 (53.9–153.3) 59.1 (26.3–146.9) 10.8(3.1–26.9) 2.2 (0.5–6.7)

Data are expressed as median (upper quartile and lower quartile) in µmols 24 h−1 (n = 40 participants for high dose EPC and 42 participants for low dose EPC and OPC treatments and placebo). High and low dose EPC = 140/70 mg monomeric catechins + 130/65 mg PC, respectively; OPC = 6.5 mg monomeric catechins + 130 mg PC. 3,4DHVL = 5‐(3’,4’‐dihydroxyphenyl)‐γ‐valerolactone; ‐4H3MVL = 5‐(4‐hydroxy‐3‐methoxyphenyl)‐γ‐valerolactone